| Document |
Document Title |
|
WO/2017/150724A1 |
The present invention provides a novel soybean allergy antigen, a diagnostic method and diagnostic kit for soybean allergies, a pharmaceutical composition including the antigen, a soybean or soybean product in which the antigen has been ...
|
|
WO/2017/115367A1 |
The present invention provides a composition and method for treating, delaying the onset, delaying progression of, reducing the incidence of or reducing the severity of amyotrophic lateral sclerosis in a subject. The composition a peptid...
|
|
WO/2017/115853A1 |
A peptide having the following sequence is added as a peptide tag to a useful protein and expressed. Ｘm(ＰＹn)qＰＺr Here, X, Y, and Z are amino acid residues each selected independently from R, G, S, K, T, L, N, Q, and H, and at l...
|
|
WO/2017/100199A1 |
The present invention provides a method for treating a subject afflicted with multiple sclerosis with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the steps of: a) admin...
|
|
WO/2017/096036A1 |
The present disclosure is directed to HER2-specific peptide reagents, methods for detecting pre-cancer (dysplasia), early cancer and/or cancer using the peptide reagents, and methods for targeting pre-cancerous (dysplastic) cells, and/or...
|
|
WO/2017/089778A1 |
The present invention relates to novel peptides derived from Homeobox protein Hox-B13 (HOXB13), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules. Also ...
|
|
WO/2017/089763A1 |
The present invention relates to novel peptides derived from DDB1 - and CUL4-associated factor 4- like protein 2 (DCAF4L2), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in compl...
|
|
WO/2017/089783A1 |
The present invention relates to novel peptides derived from Prostate specific antigen (KLK3), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules. Also p...
|
|
WO/2017/089773A1 |
The present invention relates to novel peptides derived from Structural maintenance of chromosomes protein 1 B (SMC1 B), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex ...
|
|
WO/2017/089776A1 |
The present invention relates to novel peptides derived from Melanoma-associated antigen B2 (MAGEB2), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules....
|
|
WO/2017/089765A1 |
The present invention relates to novel peptides derived from Nuclear receptor subfamily 0 group B member 1 (NR0B1), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with ...
|
|
WO/2017/089774A1 |
The present invention relates to novel peptides derived from Melanoma-associated antigen C (MAGEC1), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules. ...
|
|
WO/2017/089770A1 |
The present invention relates to novel peptides derived from melanoma-associated antigen C2 (MAGEC2), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules....
|
|
WO/2017/089775A1 |
The present invention relates to novel peptides derived from Immunoglobulin lambda-like polypeptide 1 (IGLL1), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC m...
|
|
WO/2017/086090A1 |
The present invention provides a novel peptide having specific accumulation that acts directly on pancreatic cancer cells and tissues. The present invention is a peptide of (a) or (b) below. (a) A peptide comprising an amino acid sequenc...
|
|
WO/2017/081677A1 |
The present invention provides a method for the extraction of a phytochemical, e.g., peptide or protein, from a macroalgae by applying pulsed electric field (PEF)- or continuous electric field (CEF)-treatment to said macroalgae in a solv...
|
|
WO/2017/073761A1 |
Provided are uses for collagen decomposition products or atelocollagen decomposition products having novel physiological functions. A method for forming an embryoid body of pluripotent stem cells according to an embodiment of the present...
|
|
WO/2017/066479A1 |
Compositions and methods for conferring pesticidal activity to bacteria, plants, plant cells, tissues and seeds are provided. Compositions comprising a coding sequence for a toxin polypeptide are provided. The coding sequences can be use...
|
|
WO/2017/055467A1 |
The present invention relates to polypeptides comprising at least one vinculin binding sites, to nucleic acid sequences encoding thereof and to their use for treating a proliferation and/or adhesion related disease.
|
|
WO/2017/049094A1 |
Methods for enhancing phytase thermal stability by fusing binding elements to target phytases are provided. Engineered phytases that include binding elements fused to target phytases to cause cyclization of the engineered phytases and en...
|
|
WO/2017/015119A1 |
Aspects of the disclosure relate to compositions of enzyme-binding polypeptides (EBPs) that modify the substrate specificity of an enzyme and a method for identifying an EBP that modifies substrate specificity of an enzyme binding at lea...
|
|
WO/2017/004811A1 |
Provided in the application are an active peptide for inhibiting an AMPA receptor and a preparation method and the use thereof. The preparation method for the active peptide comprises the following steps: 1) salmon skin is soaked and the...
|
|
WO/2016/179350A1 |
The present invention provides compounds that have motifs that target the compounds to cells that express integrins. In particular, the compounds have peptides with one or more RD motifs conjugated to an agent selected from an imaging ag...
|
|
WO/2016/173401A1 |
Disclosed herein are synthetic peptides and compositions comprising the same, for the treatment and/or prophylaxis of a disease, disorder and/or a condition related to inflammation. Also disclosed herein are methods of treating and/or pr...
|
|
WO/2016/164502A1 |
Disclosed herein are non-myeloablative antibody-toxin conjugates and compositions that target cell surface markers, such as the CD34, CD45 or CD117 receptors, and related methods of their use to effectively conditioning a subject's tissu...
|
|
WO/2016/147182A1 |
Disclosed are peptides comprising amino acid residues of the dimer interface of human B7-1 and B7-2 and compositions and uses thereof.
|
|
WO/2016/077413A1 |
Compositions and kits including an agent that inhibits the interaction between Disabled-2 and mutant CFTR proteins, optionally in combination with a CFTR corrector, CFTR potentiator, CAL inhibitor, mucolytic, anti- inflammatory agent or ...
|
|
WO/2016/057306A1 |
The present disclosure describes peptide inhibitors of Rho-associtated-kinase (ROCK) and their use in treating disorders including heart failure, the leading cause of combined morbidity and mortality in the United States. An inhibitory p...
|
|
WO/2016/052073A1 |
Provided are an antibody-binding polypeptide shown by any one of SEQ ID NOS: 1-18, and an adsorbent material for an antibody or antibody derivative in which this antibody-binding polypeptide is immobilized on a water-insoluble carrier Th...
|
|
WO/2016/054342A1 |
Disclosed are peptides that induce an active plant response, but not a hypersensitive response, when applied to plant tissue. These peptides also preferably exhibit improved solubility, stability, resistance to chemical degradation, or a...
|
|
WO/2016/041042A1 |
The present invention relates to synthetic peptides that bind to VEGF tyrosine kinase receptors and uses thereof. Said peptides can be used, separately or in combination, for preventing or treating diseases in which VEGF receptors play a...
|
|
WO/2016/023072A1 |
Novel analogues of the sea anemone Stichodactyla helianthus toxin ShK, and their use as, for example, therapeutic agents for treating autoimmune diseases are disclosed. The analogues comprise a ShK toxin polypeptide and an N-terminal ext...
|
|
WO/2015/176035A1 |
The invention relates to thioether monomer and dimer peptide molecules which inhibit binding of α4β7 to the mucosal addressing cell adhesion molecule (MAdCAM) in vivo.
|
|
WO/2015/170984A1 |
The present invention provides new derivatives of CATH2 or CMAP27, one of the cathelicidins. These derivatives comprise N-terminally truncated peptides, cyclic peptides, D-amino acid variants of CATH2 and its truncated derivatives, inver...
|
|
WO/2015/164581A1 |
Provided is a formulation containing an immunoconjugate comprising an anti-GCC antibody molecule and a therapeutic agent, which is superior in stability and useful as a prophylactic or therapeutic agent for gastrointestinal cancer and th...
|
|
WO/2015/157820A1 |
A method and composition for eliciting an immune response to group A streptococcal bacteria in a mammal is provided, which includes administering to the mammal an M protein fragment, variant or derivative thereof and a SpyCEP protein or ...
|
|
WO/2015/138494A1 |
Disclosed herein are novel anti-microbial peptides with inhibitory activity against M. tuberculosis and streptococcus bacteria. Additionally, a method for designing novel anti-microbial peptides is disclosed.
|
|
WO/2015/111407A1 |
An object of the present invention is to provide a binding agent capable of binding to rare earth materials such as rare earths and inorganic compounds thereof. Provided is a rare earth material-binding agent including a peptide capable ...
|
|
WO/2015/091613A1 |
The present invention relates to Enterokinase-cleavable polypeptides comprising an Enterokinase cleavage site connected to a polypeptide and their use for making the target polypeptide by expression. The invention also relates to DNA seq...
|
|
WO/2015/038933A1 |
The present application provides stable peptide-based Akt capture agents and methods of use as detection and diagnosis agents and in the treatment of diseases and disorders. The application further provides methods of manufacturing Akt c...
|
|
WO/2015/024955A1 |
The present description provides compositions and methods for producing therapeutic oligomeric compounds. In another aspect the description provides methods for administering the oligomeric compounds for the treatment and prevention of d...
|
|
WO/2014/186937A1 |
The present invention provides a preparation method of mussel adhesive protein gel, comprising: acquiring or preparing mussel adhesive protein, acquiring or preparing gel matrix, admixing the gel matrix and liquid mussel adhesive protein...
|
|
WO/2014/180534A1 |
The invention relates to a peptide, up to more than 50% of which consists of sequence segments of the formula: -(An-Bm-C0)-. The invention also relates to a conjugate containing the peptide and at least one covalently bonded active ingre...
|
|
WO/2014/177042A1 |
Provided in the present invention is a linker and a preparation method thereof, wherein one end of the linker may covalently link a small molecule compound and the like and the other end may specifically and covalently link a targeting s...
|
|
WO/2014/175284A1 |
[Problem] Based on the prediction that the rules for DNA recognition possessed by a PPR motif may also be used in DNA recognition, perform analysis of PPR protein that is active in DNA binding, and search for a PPR protein that has such ...
|
|
WO/2014/167371A1 |
The present invention concerns novel antibiotic compounds having general formula (I), a process for their preparation, their pharmaceutical acceptable salts and the pharmaceutical compositions containing them as well as their use as anti...
|
|
WO/2014/159941A1 |
Isolated polypeptides that possess an a- sheet structure are disclosed that can be used to treat or diagnose amyloid diseases.
|
|
WO/2014/157169A1 |
The present invention addresses the problem of providing a cleaning agent composition which is environmentally friendly and therefore can be used in the open air and the like without causing problems, and which is effective for the remov...
|
|
WO/2014/137930A1 |
Provided herein are compounds, compositions, and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, the compounds are according to Formula 2001; where PD, Base, RA and RB are as provid...
|
|
WO/2014/110438A1 |
The present disclosure relates to, among other things, compounds that bind to the C5d domain of complement component C5 (e.g., human complement component C5) and compounds that comprises all or part of human C5d. In some embodiments, the...
|
